Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of tigatuzumab (CS-1008) plus irinotecan vs irinotecan in metastatic colorectal cancer
2007-005675-34Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tigatuzumab in colorectal adenocarcinoma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Apr 2009; status: completed.
02
Drugs
tigatuzumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2007-005675-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005675-34.